中国医药“出海”更便捷更安全

Core Viewpoint - The China-ASEAN Regional Pharmaceutical Trading (Procurement) Platform has been launched to facilitate cross-border online transactions and settlements for Chinese pharmaceutical companies entering ASEAN and SCO countries, marking a significant step in enhancing the convenience and safety of "going global" for Chinese medicine [1][2]. Group 1: Platform Overview - The platform has quickly gathered a wealth of pharmaceutical enterprises and product resources, currently listing 781 types of drugs and 1,652 categories of medical consumables and equipment, with 114 domestic leading pharmaceutical companies and 10 international buyers registered [2]. - The platform aims to create a comprehensive closed-loop for pharmaceutical transactions, covering the entire process from application registration to procurement declaration, transaction matching, and settlement delivery [2]. Group 2: Transaction Features - The platform provides a streamlined experience for cross-border transactions, offering a model where enterprises can showcase their products and buyers can connect directly, reducing communication costs and market risks [2]. - Multi-currency cross-border payment services and compliance risk control are provided by Lianlian International, enhancing the efficiency and security of cross-border transactions [3]. Group 3: Platform Characteristics - The platform is characterized by its timeliness, authority, innovation, service orientation, and openness, serving as a bridge for Chinese medicine to connect with international standards [4][5]. - It actively supports national diplomatic efforts and deepens cooperation with ASEAN and SCO countries in medical security and pharmaceutical policies [4]. Group 4: Future Challenges and Strategies - Despite initial successes, challenges remain, including standard recognition barriers, information asymmetry, geopolitical issues, and competitive pressures among domestic companies [6]. - The platform aims to improve operational mechanisms, enhance transaction efficiency, promote mutual recognition of pharmaceutical regulations, build a professional terminology database, and implement impactful healthcare projects in ASEAN countries [6][7][8].